- Conditions
- IPMN, IPMN, Pancreatic
- Interventions
- Sulindac 400 MG, Placebo
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- repaglinide, metformin, repaglinide and metformin combination tablet
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury, Metformin
- Interventions
- Metformin low dose, Metformin high dose, Placebo
- Drug
- Lead sponsor
- Hernando Gomez
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension, Diabetes Mellitus, Type 2
- Interventions
- Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
- Drug · Device · Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 35 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
- Conditions
- Diabetes Mellitus
- Interventions
- IDegLira, Insulin Degludec (U-100), Insulin Aspart
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- VH4524184, Itraconazole, Rifabutin, Phenytoin, Metformin, Digoxin
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- High-dose colesevelam, Low-dose colesevelam
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- T2DM With Inadequate Glycemic Control
- Interventions
- CS02 tablet and placebo tablet
- Drug
- Lead sponsor
- Center Laboratories, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • Coral Gables, Florida • Hialeah, Florida
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 24
- States / cities
- Muscle Shoals, Alabama • Glendale, Arizona • Phoenix, Arizona + 21 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
- Conditions
- Overweight or Obesity, Type2 Diabetes Mellitus
- Interventions
- GSBR-1290, Placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 39
- States / cities
- Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more
- Conditions
- Glioblastoma
- Interventions
- Ketogenic Diet, Metformin
- Other · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Poor Glycemic Control
- Interventions
- Metformin, Glargine insulin, Glulisine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Metformin, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 12
- States / cities
- Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
- Conditions
- Metabolic Syndrome
- Interventions
- Metformin, Placebo, Low Intensity Exercise, High Intensity Exercise
- Drug · Behavioral
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 28
- States / cities
- Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
- Conditions
- Glioblastoma
- Interventions
- Paxalisib, Metformin, Ketogenic Diet
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Low Metformin, Metformin, Mid Metformin, High Metformin
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
- Conditions
- NAFLD
- Interventions
- Leu-Met-Sil 0.5, Leu-Met-Sil 1.0, Placebo
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 13
- States / cities
- Chino, California • San Diego, California • Wheat Ridge, Colorado + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Low Metformin, Mid Metformin, High Metformin, Metformin
- Drug
- Lead sponsor
- NuSirt Biopharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
- Conditions
- Short Segment Barrett's Esophagus, Long Segment Barrett's Esophagus
- Interventions
- Omeprazole, Vitamin D3, upper endoscopy, Metformin
- Drug · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Beachwood, Ohio • Cleveland, Ohio